TNX-102 SL for Depression

(HORIZON Trial)

This trial tests whether TNX-102 SL, a sublingual tablet, can treat moderate to severe depression in adults. The study aims to determine if the drug improves depression symptoms and to identify any side effects. Participants will take either the drug or a placebo (a pill with no active ingredients) every night for six weeks. Individuals who have experienced major depression for at least six weeks but not longer than 18 months, and who can speak English, may be suitable for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Yes, you will need to stop taking antidepressants at least 4 weeks before starting the trial, except for fluoxetine, which requires a 6-week break.

Research has shown that TNX-102 SL is generally well-tolerated. In earlier studies, some participants reported drowsiness, changes in taste, and unusual sensations in their mouths. These side effects occurred more frequently in those receiving the treatment than in those on a placebo.

Other studies involving fibromyalgia patients found TNX-102 SL to be well-tolerated, with most people experiencing no major issues. A common side effect was mouth numbness, though it wasn't considered serious. Additionally, TNX-102 SL had fewer side effects like weight gain, often associated with traditional antidepressants.

TNX-102 SL is unique because it offers a new approach to treating depression with its sublingual delivery method. Unlike traditional antidepressants, which are usually taken orally and can take weeks to show effects, TNX-102 SL is designed to be placed under the tongue, allowing for quicker absorption into the bloodstream. This could lead to faster relief of depressive symptoms. Additionally, the active ingredient in TNX-102 SL might offer a different mechanism of action compared to standard treatments like SSRIs and SNRIs, which typically target serotonin and norepinephrine pathways. Researchers are hopeful that this could provide new benefits for patients who do not respond well to existing medications.

Research has shown that TNX-102 SL, which participants in this trial may receive, yields promising results in easing depression symptoms. It also helps reduce pain and improve sleep for people with fibromyalgia and PTSD (post-traumatic stress disorder). Importantly, TNX-102 SL appears to have fewer common side effects of antidepressants, such as weight gain and changes in blood pressure. These findings suggest that TNX-102 SL could be a potential treatment for major depressive disorder, with added benefits for sleep and pain relief.¹³⁵⁶⁷